Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin final report update 5

In the United States, coronary heart disease and cardiovascular disease account for nearly 40% of all deaths each year. Coronary heart disease continues to be the leading cause of mortality and a significant cause of morbidity among North Americans. In 2006, coronary heart disease claimed 607 000 li...

Full description

Bibliographic Details
Main Author: Smith, M. E. Beth
Corporate Authors: Drug Effectiveness Review Project, Oregon Health & Science University Evidence-based Practice Center, Oregon Health & Science University
Format: eBook
Language:English
Published: Portland, Or. Oregon Health & Science University c2009, 2009
Series:Drug class reviews
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:In the United States, coronary heart disease and cardiovascular disease account for nearly 40% of all deaths each year. Coronary heart disease continues to be the leading cause of mortality and a significant cause of morbidity among North Americans. In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia
Item Description:Title from PDF cover. - "November 2009.". - Mode of access: Internet